Literature DB >> 3994189

Hypercalcemia in pheochromocytoma. Evidence for a novel mechanism.

A F Stewart, J L Hoecker, L E Mallette, G V Segre, T T Amatruda, A Vignery.   

Abstract

A child with a pheochromocytoma had hypercalcemia but no evidence for excessive parathyroid hormone secretion from the parathyroid glands or the pheochromocytoma. Therapy with the catecholamine synthesis inhibitor metyrosine (alpha-methyltyrosine) reversed the catecholamine excess but had no effect on the hypercalcemia. Adrenalectomy promptly reversed the hypercalcemia. Extracts of the tumor contained a substance(s) that produced both potent in-vitro bone resorption and striking adenylate-cyclase-stimulating activity in renal cortical membranes. This stimulating activity was due to activation of the parathyroid hormone receptor/adenylate cyclase complex but was not due to parathyroid hormone. Our findings document hypercalcemia in association with pheochromocytoma and show that hypercalcemia occurred in the absence of previously proposed mechanisms. We also provide preliminary characterization of the presumed responsible substance(s) and suggest that this substance(s) may be related to that associated with the humoral hypercalcemia of malignancy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994189     DOI: 10.7326/0003-4819-102-6-776

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels.

Authors:  A Benit; J Allard; J Rimailho; J Fauvel; G Escourrou; D Vezzosi; F Donadille; A Bennet; P Caron
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Plasma gut hormone levels in 37 patients with pheochromocytomas.

Authors:  A I Vinik; B Shapiro; N W Thompson
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

3.  Somatostatin analogue treatment for malignant hypercalcaemia.

Authors:  M Harrison; N James; K Broadley; S R Bloom; R Armour; S Wimalawansa; D Heath; J Waxman
Journal:  BMJ       Date:  1990-05-19

4.  Humoral hypercalcemia complicating adenosquamous carcinoma of the proximal colon.

Authors:  C H Berkelhammer; A L Baker; G E Block; D G Bostwick; F Michelassi
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

5.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

6.  Malignant phaeochromocytoma and hypercalcaemia.

Authors:  J A Bridgewater; W A Ratcliffe; N J Bundred; C W Owens
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

Review 7.  Paraneoplastic manifestations in children.

Authors:  J H de Graaf; R Y Tamminga; W A Kamps
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

8.  Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy.

Authors:  K Ikeda; M Mangin; B E Dreyer; A C Webb; J T Posillico; A F Stewart; N H Bander; E C Weir; K L Insogna; A E Broadus
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

9.  Effect of methylprednisolone on bone mineral density in rats with ovariectomy-induced bone loss and suppressed endogenous adrenaline levels by metyrosine.

Authors:  Mehmet Yilmaz; Unal Isaoglu; Turan Uslu; Kadir Yildirim; Bedri Seven; Fatih Akcay; Ahmet Hacimuftuoglu
Journal:  Indian J Pharmacol       Date:  2013 Jul-Aug       Impact factor: 1.200

10.  The effect of metyrosine/prednisolone combination to oophorectomy-induced osteoporosis.

Authors:  Suleyman Salman; Serkan Kumbasar; Ahmet Hacimuftuoglu; Berna Ozturk; Bedri Seven; Beyzagul Polat; Cemal Gundogdu; Elif Demirci; Kadir Yildirim; Fatih Akcay; Turan Uslu; Ferrah Tuncel Daloglu; Halis Suleyman
Journal:  Iran J Reprod Med       Date:  2012-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.